- Home
- CRAN vs LRMR Comparison
CRAN vs LRMR Comparison
Compare CRAN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAN | LRMR |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.3M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRAN | LRMR |
|---|---|---|
| Price | $10.14 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 90.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.72 |
| 52 Week High | $10.21 | $6.42 |
Technical Indicators
Market Signals| Indicator | CRAN | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 57.36 |
| Support Level | $10.13 | $3.01 |
| Resistance Level | N/A | $4.21 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 12.50 | 68.31 |
Price Performance
Historical ComparisonAbout CRAN Crane Harbor Acquisition Corp. II Class A Ordinary Shares
Crane Harbor Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.